{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
abarelix
to a specific field?
There is one exact (name or code) match for abarelix
Status:
US Previously Marketed
Source:
PLENAXIS by SPECIALITY EUROPEAN
(2003)
Source URL:
First approved in 2003
Source:
PLENAXIS by SPECIALITY EUROPEAN
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Abarelix is a synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Abarelix binds to the gonadotropin releasing hormone receptor and acts as a a potent inhibitor of gonadotropin secretion. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Status:
US Previously Marketed
Source:
PLENAXIS by SPECIALITY EUROPEAN
(2003)
Source URL:
First approved in 2003
Source:
PLENAXIS by SPECIALITY EUROPEAN
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Abarelix is a synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Abarelix binds to the gonadotropin releasing hormone receptor and acts as a a potent inhibitor of gonadotropin secretion. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT01339299: Phase 4 Interventional Completed Controlled Ovarian Stimulation
(2009)
Source URL:
First approved in 1975
Source:
BLA021663
Source URL:
Class:
PROTEIN
